Status:
COMPLETED
Effects of Marijuana on Symptoms of OCD
Lead Sponsor:
New York State Psychiatric Institute
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this pilot research study is to test whether certain components of the marijuana plant, known as "cannabinoids", may help to reduce symptoms in patients with OCD. Specifically, patients...
Detailed Description
Prior research suggests that certain areas of the brain are receptive to chemicals like those found in the cannabis (marijuana) plant, known as cannabinoids, and that these regions may be involved in ...
Eligibility Criteria
Inclusion
- Age 21-55
- Physically healthy
- Diagnosed with OCD
- Current marijuana user
- Women of childbearing potential must be using an effective form of birth control
- Not currently taking psychotropic medications
- Ability to provide informed consent
Exclusion
- History of any significant medical condition that may increase the risk of participation
- Females who are pregnant or nursing
- If female, not pregnant
- Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation
- Current substance use disorder
- Severe depression or positive urine toxicology (other than THC) at screening, or any adverse reaction to a cannabinoid
- Patients who are seeking treatment for substance abuse
- Patients who are planning to begin a course of cognitive-behavioral therapy within 8 weeks of beginning the study
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2020
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03274440
Start Date
October 1 2017
End Date
October 29 2020
Last Update
November 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032